<International Circulation>:  Do we see any side effects in children we wouldn’t normally see?

　　《国际循环》：在儿童中有我们不容易看见的副作用吗？

Dr. Al-Rassadi: Although most of the studies on children average four to five years， people have tested puberty， growth， hormones， liver function and so on， and it has been shown to be very safe to use a statin in this age group. We don’t have long-term studies yet， but so far， the consensus is that it is safe to use statins in this age group.

　　Al-Rassadi博士: 尽管大部分关于儿童的研究平均年龄为4～5岁，研究者还是对青春期、生长、荷尔蒙、肝功能等进行了检测，研究结果显示在这个年龄组使用他汀类药物是非常安全的。虽然我们没有长期研究，但是到目前为止，这个年龄的患者使用他汀类药物是安全的。

<International Circulation>: Your presentation was entitled， “Screening – Where are we now?” Are we doing enough?

　　《国际循环》：您的演讲题目是“筛查 –我们进行到了那个阶段？”我们现在做的足够吗？

Dr. Al-Rassadi: If we just depend on clinical criteria or lipid levels when looking at new cases of familial hypercholesterolemia， there will be a lot of false negatives. DNA analysis is now one of the options that is used to screen and diagnose for people with familial hypercholesterolemia. It is also the confirming technique. There have been a lot of national screening programs， the oldest of which has been conducted in the Netherlands where they have twenty years of cascade screening. It is like a network of lipid clinics involved with other physicians and they have been very successful. There are a lot of studies looking at cost-effectiveness for example， which indicate that it is very cost-effective in saving lives.

　　Al-Rassadi博士: 如果我们在检测新的家族性高胆固醇患者时仅依赖于临床标准或血脂水平，就会出现很多漏诊病例。目前DNA检测是用于筛选和诊断家族性高胆固醇患者的一种选择，同时也是确诊技术。有很多国家筛查项目，最早的一项在荷兰实施，荷兰已经进行了20年的级联筛查。他们的这一系统就像一个联合了其他内科医生的血脂诊所网络，非常成功。有很多研究对成本效益进行了分析，例如有哪些措施在挽救患者生命的同时又有最佳的成本效益。

<International Circulation>:  Is there a screening program in Oman?

　　《国际循环》：在阿曼有筛查计划吗？

Dr. Al-Rassadi: Actually not yet. In Saudi Arabia， they are starting their screening program in the near future. We had a small pilot study looking at the prevalence of familial hypercholesterolemia but we are planning now， in collaboration with our colleagues in the Netherlands， to start our national screening program.

　　Al-Rassadi博士: 目前还没有。不久将会在沙特阿拉伯开始实施筛选项目。我们进行了一项小的前期研究来分析家族性高胆固醇血症的流行病学情况，但是现在我们计划与我们荷兰的同事一起开始我们的国家筛查计划。

<International Circulation>: How prevalent are screening programs in the developing world?

　　《国际循环》：在发展国家这种筛查项目很普遍吗？

Dr. Al-Rassadi: It is not very prevalent to tell you the truth. This is related maybe to availability of resources and interest as well.

　　Al-Rassadi博士: 很难告诉你这一问题的真实情况。这可能依赖于资源的可用性及人们的兴趣。

<International Circulation>:  You said that it was cost-effective. By cost-effective did you mean it saved costs or it didn’t cost very much?

　　《国际循环》：您说过这是有成本效益的。谈到成本效益您的意思是这种项目节约成本还是他们的花费并不多？

Dr. Al-Rassadi: Although it is costly， it saves lives so in terms of overall costs it is cost-effective.

　　Al-Rassadi博士: 虽然这种项目很昂贵，它还是挽救了很多生命，所以从总体的花费来说这是非常划算的。